[18F]BO was developed based on the Olaparib scaffold to quantitate the therapeutic doses of Olaparib to inhibit PARP in vivo in ovarian cancer models and delineate the biodistribution of the drug (14). The gene discussed is PARP1; the disease is ovarian carcinoma.